Want to join the conversation?
In Jan. 2016, $ABBV announced the commencement of a Phase 3 clinical trial program to study the use of its once-daily formulation of ABT-494, its internally developed investigational selective Janus Kinase 1 inhibitor, for the treatment of rheumatoid arthritis. A Phase 2 trial of ABT-494 for the treatment of Crohn's disease is also ongoing.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)